23 results about "Mydriasis" patented technology

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention discloses a free-form surface-based focusing-free fundus imaging system, and belongs to the technical field of fundus imaging. The system comprises a light source module, a light splitting module, a light condensing module, a scanning module, a transmitting mirror group, an eyepiece group and a light detection module, the entrance pupil of the transmitting mirror group is located at the focus of the first parabolic mirror, and the eye pupil is located at the focus of the second parabolic mirror. The transmission lens group is used for correcting field aberration and human eye diopter aberration and comprises a first lens, a second lens, a first free-form surface lens, a second free-form surface lens, a third lens and a fourth lens; the third lens and the fourth lens converge the light of the eyepiece group to form a first image surface; the first free-form surface lens and the second free-form surface lens modulate the phase of the first image surface and correct diopter aberration; the first lens and the second lens perform aberration correction on the exit pupil and compress the light size to match the scanning module. The system has the advantages of ultra-wide angle, high resolution, no mydriasis and simple operation.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention relates to an optimization method for positioning measurement of an implanted crystalline lens after an ophthalmic operation, which comprises the following steps of: scanning an implanted astigmatism correction type artificial crystalline lens by using frequency sweep source optical coherence tomography (SS-OCT) to obtain image data containing a positioning mark, processing the image data by using a deep learning framework, and obtaining a positioning mark of the implanted astigmatism correction type artificial crystalline lens. Automatically identifying the astigmatism mark on the intraocular lens, and calculating the actual implantation axial position of the intraocular lens according to the identified astigmatism mark. The method has the advantages that axial position measurement can be completed without mydriasis, discomfort of a patient is reduced, dependence on operators is reduced, and measurement accuracy and efficiency are improved. The system comprises SS-OCT equipment and a deep learning processing module, and realizes automatic and non-invasive measurement of the implantation axial position of the artificial lens.

The present invention provides a low-concentration atropine nanoemulsion, its preparation method and application, belonging to the field of pharmaceutical technology. In the present invention, atropine is used as the main drug, and oil and surfactant are successfully used to encapsulate atropine in the oil phase, solving the problem of poor stability of atropine aqueous solution, realizing the slow release of atropine in the eye, improving the bioavailability of the drug, reducing adverse reactions such as mydriasis, photophobia, and dry eye, having good biocompatibility, and overcoming the problem of irritation to the eye caused by too high local concentration of ordinary eye drops. The nanoemulsion and lower-concentration nanoemulsion of the present invention have high bioavailability, have the effect of effectively delaying the development of myopia, have high safety, small side effects, and good application prospects.

1. The name of this design product: Manual fundus camera. 2. Purpose of the product of this design: integrating the color photography function of the non-mydriatic fundus camera. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention discloses a deuterated compound of benzodiazepine and application thereof, the deuterated compound of benzodiazepine has the following general formula: in the formula, R1 and R2 are independently selected from ethyl or deuterated ethyl, R3 to R18 are independently selected from H group or deuterated group, and R1 to R18 at least contain one deuterated group. The deuterated compound of benzodiazepine or the pharmaceutically acceptable salt, hydrate or solvent compound thereof provided by the invention has a muscarinic M2 receptor antagonism effect, and compared with a known selective M2 receptor inhibitor, the compound provided by the invention has better inhibitory activity and pharmacodynamic performance, has little influence on the activity of an M3 receptor, and can be used for preparing a novel compound of benzodiazepine or a pharmaceutically acceptable salt, hydrate or solvent compound of benzodiazepine. The side effect of pupil dilation (mydriasis) is avoided, and the composition has a good development prospect in clinical application of treating myopia, preventing myopia and / or inhibiting myopia development.

Disclosed are a deuterated compound of benzodiazepine, and a use thereof. The deuterated compound of benzodiazepine has the following general formula (I), R1 and R2 being independently selected from ethyl or deuterated ethyl, R3-R18 being independently selected from hydrogen or deuterium, and R1-R18 containing at least one deuterium. The deuterated compound of benzodiazepine provided by the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, has antagonistic activity against muscarinic M2 receptors. Compared with known selective M2 receptor inhibitors, the compound of the present invention has better inhibitory activity and pharmacodynamic properties, and has minimal activity on M3 receptors, thereby avoiding the side effect of pupil dilation (mydriasis). It has promising prospects for clinical applications in treating myopia, preventing myopia, and / or inhibiting the progression of myopia.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The application discloses a method for establishing an angle-closure glaucoma animal model. The method comprises the following steps: performing mydriasis on an eye of an animal model after general anesthesia, performing local anesthesia on an eye surface of the model eye after 10 minutes; after the pupil of the model eye is reduced, eye gel is added to the eye surface; a semiconductor laser is used to uniformly hit a plurality of laser points at an iris margin; and eye drops are added to the eye surface after laser treatment. The method uses a 532nm laser to hit the iris margin, causes local edema of the iris margin, narrows a passage through which aqueous humor flows from the posterior chamber into the anterior chamber, and increases the pressure of the posterior chamber. The method can keep the high intraocular pressure of the established angle-closure glaucoma animal model between 20-30mmHg, the success rate is 70%, the high intraocular pressure can be maintained for more than one week, no wound is caused on the eye of the animal model, there is no inflammatory reaction on the eye surface, the cornea has no edema and new blood vessels, and the operation of the model can be completed within 10 minutes.

The invention relates to the technical field of biological medicine, in particular to sophocarpine and application of sophocarpine in inhibiting formation of subretinal fibrosis, and the sophocarpine comprises the following steps: selecting 7-week-old male C57BL / 6J mice, adaptively feeding the mice for 1 week, and performing 12-hour illumination / 12-hour dark circulation at the environment temperature of 22-25 DEG C; the method comprises the following steps of: performing intraperitoneal injection of thiobarbital sodium on a C57 mouse fed for 1 week for anesthesia, realizing muscle relaxation by using hypnotic, and anesthetizing ocular surface by using 0.4% tetracaine and 0.5% tropicamide mydriasis; a mouse is randomly divided into a control eye and an experiment eye, and 1 microliter of PBS containing 1.5% of DMSO is injected into the control eye to serve as a carrier for control. The invention finds that injection of sophocarpine in vitreous cavity can inhibit RPE cell epithelial-mesenchymal transition, can be used for preventing or treating age-related macular degeneration subretinal fibrosis, may become a new medicine for treating subretinal fibrosis, has important value for inhibiting EMT of RPE cells, can also inhibit EMT of other cells, and can be used for preventing or treating age-related macular degeneration subretinal fibrosis and treating age-related macular degeneration subretinal fibrosis. Therefore, the method has potential application value on diseases caused by cell EMT.

The invention discloses a focusing-free ellipsoidal fundus imaging system, and belongs to the technical field of fundus imaging. The system comprises a light source module, a light splitting module, a light condensing module, a scanning module, a light detection module, a focusing-free transmitting mirror group and an ellipsoidal reflector, light rays sequentially pass through the light splitting module, the light condensing module, the scanning module, the focusing-free transmitting mirror group and the ellipsoidal reflector and reach human eyes through pupils; reflected light of human eyes sequentially passes through the ellipsoidal reflector, the focusing-free transmitting mirror group, the scanning module, the light condensing module and the light splitting module to the light detection module, and the light detection module converts a light signal into a digital image. A human eye pupil is located at a first focus of the ellipsoidal reflector, and an entrance pupil of the focusing-free transmitting mirror group is located at a second focus; the ellipsoidal reflector transmits incident light to human eyes and transmits reflected light back to the focusing-free transmitting mirror group; and the focusing-free lens group is used for correcting field aberration and compensating human eye diopter aberration. The system has the advantages of ultra-wide angle, high resolution, no mydriasis and simple operation.

The invention provides an automatic mydriasis device. The automatic mydriasis device comprises a head-mounted structure, and an eyedrop spraying system, an audio and video guiding unit and an image analysis system which are mounted on the head-mounted structure, the head-mounted structure covers the eyes to form a darkroom, and the audio and video guide unit guides the eyes to open, rotate or close; the eyedrop spraying system sprays eyedrops to eyeballs according to set time and dosage; the image analysis system is used for shooting images of eyeball shapes and movement, controlling the audio and video guide unit and the eyedrop spraying system to work according to system settings, spraying eyedrops, and judging the pupil diffusion effect through image recognition under the guidance of sound and images by the audio and video guide unit. The invention further provides a mydriasis method adopting the automatic mydriasis device and a mydriasis effect detection method.

The invention provides methods, compositions, and kits containing an alphaadrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The present invention discloses a cataract image classification method and system based on self-supervised pre-training, which relates to the field of image classification technology. The specific steps are: constructing a mask template based on a dilated anterior segment photographic image; extracting a slit lamp photographic image from a local data set, and performing image and operation on the slit lamp photographic image and the mask template to obtain a mask image; building an image restoration model; using the image restoration model to perform self-supervised pre-training on the mask image to obtain a self-supervised pre-training weight; constructing an image classification model based on the image restoration model, the self-supervised pre-training weight and a classification module; obtaining an image to be identified, and obtaining a classification result based on the image classification model. The present invention can reduce the dependence on the number of samples through self-supervised pre-training, and can also improve the accuracy of classification and recognition.

The invention discloses a device for distinguishing gaze properties, which comprises a shell, a fixing structure is arranged at the top end of the shell, a black spot generating device is arranged in the shell, a combined mirror is arranged on the black spot generating device, a semi-permeable mirror is arranged at the upper end of the black spot generating device and is inclined, and meanwhile, a silica gel eyeshade and a convex lens are arranged at the left end of the shell. The fixing structure is used for fixing the circle center marking plate, meanwhile, the circle center marking plate is provided with a center alignment device and an alignment device light source, a light source radiator is arranged in the shell, a control key and a card reader are arranged outside the shell, and the combined mirror is a light filtering and dodging combined mirror. The method has the advantages of being low in cost, low in false positive rate, free of mydriasis and the like.

The invention belongs to the field of ophthalmology detection, and particularly relates to a method for rapidly calculating equivalent spherical power and a spherical power value based on eyeball morphological parameters. According to the method, the morphologies of the eyeballs of a person to be measured, including the anterior chamber depth AD, the ocular axis length AL, the crystal thickness LT, the cornea anterior surface K1 value, the cornea anterior surface K2 value and the like, are measured twice, and an adaptive model is provided according to the variation of the morphological parameters of the eyeballs measured twice; and the measured parameter values are substituted into the model according to the model, so that the equivalent spherical power and the numerical value of the spherical power can be quickly and accurately obtained. According to the method provided by the invention, only one time of mydriasis optometry needs to be carried out on children and teenagers within four years, tedious operation of mydriasis in the subsequent examination process is omitted, multiple check coefficients are added into the provided model, and the accuracy of model calculation is relatively high.